

MATERIAL SAFETY DATA SHEET

Benzphetamine Hydrochloride Tablets 50 mg

Revision Date: 03-07-07

SECTION 1: PRODUCT IDENTIFICATION

| | |
|-------------------------------|---|
| Product Name | Benzphetamine Hydrochloride Tablets, 50 mg |
| Common Name/Trade Name | Benzphetamine Hydrochloride Tablets, 50 mg |
| Manufacturer | Paddock Laboratories, Inc. |
| Synonyms | NA |
| Chemical Name | <i>d</i> -N,a-Dimethyl-N-(phenylmethyl)-benzeneethanamine hydrochloride |
| Chemical Family | Phenethylamine derivative |
| Chemical Formula | C ₁₇ H ₂₁ N·HCl |

SECTION 2: HAZARDOUS INGREDIENTS

| CHEMICAL NAME | CAS# | % | OSHA PEL | ACGIH TLV | IDLH |
|---------------------------------------|------------|----|----------|-----------|------|
| Benzphetamine HCl | 5411-22-3 | NE | NE | NE | NA |
| Microcrystalline Cellulose, NF | 9004-34-6 | NE | NE | NE | |
| Lactose Monohydrate, NF | 64044-51-5 | NE | NE | NE | |
| Sodium Starch Glycolate, NF | 9063-38-1 | NE | NE | NE | |
| *Magnesium Stearate, NF | 557-04-0 | NE | NE | NE | |
| *Colloidal Silicon Dioxide, NF | 7631-86-9 | NE | NE | NE | |
| Opadry II, 40L14336, Pink (film coat) | NA | NE | NE | NE | |

* These ingredients are at concentrations of less than 1%.

SECTION 3: HAZARDS IDENTIFICATION

| | |
|---|--|
| Adverse Effects | Adverse effects may include increase in blood pressure; skin rash or hives; swelling of feet and lower legs; trouble breathing; stroke or impending stroke (severe headache, numbness on one side of body or face); difficult, painful, or increased urination; talking, feeling, and acting with uncontrolled excitement; mental depression; fast or irregular heartbeat; chest pain; fainting; psychosis, (paranoia, hallucinations); central nervous system stimulation (false sense of well being, irritability, nervousness, restlessness, trembling or shaking, trouble sleeping) followed by drowsiness, fatigue, or mental depression; constipation; dizziness, dry mouth headache; nausea or vomiting; stomach cramps or pain; blurred vision; changes in sexual desire and ability; diarrhea; drowsiness, increased sweating; and unpleasant taste. Possible allergic reaction to material if inhaled, ingested or in contact with skin. |
| Potential Acute Health Effects | Possible eye, skin, gastrointestinal and/or respiratory tract irritation. |
| Potential Chronic Health Effects | Possible hypersensitization, tolerance, and physical or psychological dependence. Inhalation: May cause irritation. Remove to fresh air. |
| Pregnancy | Pregnancy category X. Benzphetamine hydrochloride is not to be used therapeutically during pregnancy because it may cause harm to the fetus. Clinical reports in humans and studies in animals have shown that amphetamines (a related group of chemicals) cause birth defects and abnormal development in the fetus. |

| |
|--------------------------------------|
| SECTION 4: FIRST AID MEASURES |
|--------------------------------------|

| | |
|---------------------------|---|
| Skin Exposure | May cause irritation. Flush with water. |
| Eye Exposure | May cause irritation. Flush immediately with copious amounts of water for at least 15 minutes. Obtain emergency medical treatment. |
| Inhalation | Inhalation exposure is not expected to occur. If symptoms develop, remove to a well ventilated area and seek medical attention. |
| Ingestion | May cause irritation and toxicity. Flush out mouth with water. This material is absorbed from the gastrointestinal tract. Obtain emergency medical treatment. |
| Overdose Treatment | <p>Treatment is symptomatic and supportive and may include the following:</p> <ol style="list-style-type: none"> 1. Do not induce vomiting. Administer activated charcoal. Gastric emptying is not necessary if activated charcoal can be given promptly. 2. Barbiturate sedatives or diazepam are sometimes used to control excessive CNS stimulation. 3. Treat severe hypertension with a parenteral vasodilator such as phentolamine or nitroprusside. 4. Use beta-adrenergic blocking agent for control of tachycardia. Use intravenous lidocaine for cardiac arrhythmia. 5. Use intravenous diazepam to control seizures; use phenytoin if seizures are refractory to diazepam. When hyperthermia and rhabdomyolysis are present, curarization may be required. |

6. Manage hypotension with intravenous fluids.
7. Monitor cardiovascular and respiratory function; monitor body temperature. Use a mechanical respirator if necessary.
8. Protect patient from self-injury by use of restraints if necessary.
9. Dialysis and hemoperfusion are not effective. Acidification of urine and forced diuresis may enhance elimination.

SECTION 5: FIRE / EXPLOSION HAZARDS & FIREFIGHTING MEASURES

| | | |
|--|---|-----------|
| Flammability of the Product | NA | |
| Auto-ignition Temperature | NA | |
| Flash Points | NA | |
| Flammable Limits (in air by volume, %) | Lower: NA | Upper: NA |
| Fire Extinguishing Equipment | Use extinguishing agent suitable for type of surrounding fire. Water Spray: OK Foam: OK Carbon Dioxide: OK Dry Chemical: OK | |
| Unusual Fire and Explosion Hazards | None | |
| Explosion Hazards in presence of Various substances | NA | |
| Firefighting Procedures | For fires beyond the incipient stage, emergency responders in the immediate hazard area should wear bunker gear. When the potential chemical hazard is unknown, in enclosed or confined spaces, or when explicitly required by the DOT <i>Emergency Response Guidebook</i> , a self-contained breathing apparatus should be worn. In addition, wear other appropriate protective equipment as conditions warrant (see Section 8). Isolate immediate hazard area and keep unauthorized personnel out. Contain spill if it can be done with minimal risk. Move undamaged containers from immediate hazard area if it can be done with minimal risk. Cool equipment exposed to fire with water, if it can be done with minimal risk. | |

SECTION 6: SPILL AND LEAK PROCEDURES

| | |
|---------------|--|
| Spills | Clean area. Dispose in accordance with all Federal, State and local regulations. |
|---------------|--|

SECTION 7: HANDLING AND STORAGE

| | |
|---------------------------------------|---|
| Work and Hygiene Practices | As with all chemicals, avoid getting this product on you or in you. Do not eat, drink or smoke or apply cosmetics while handling the product. Wash hands thoroughly after handling. |
| Storage and Handling Practices | Keep out of reach of children. Store at controlled room temperature between 15° – 30° C (59°-86° F) |

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

| | |
|-----------------------------------|--|
| Engineering Controls | Use adequate ventilation when handling raw materials |
| <u>Personal Protection</u> | |
| Respiratory Protection | No special requirements under normal conditions of use. |
| Eye Protection | Approved eye protection to safeguard against potential eye contact, irritation or injury is recommended. |
| Hand Protection | Gloves are recommended. |
| Body Protection | No special requirements. |

SECTION 9: PHYSICAL / CHEMICAL PROPERTIES

| | |
|--------------------------------------|--|
| Physical state and appearance | Pink round tablet bisected on one side with the debossed logo 'PAD 0116' on the same side. |
| Molecular Weight | NA |
| Boiling Point | NA |
| Vapor Density (AIR=1) | NA |
| Vapor Pressure (mm Hg) | NA |
| Melting/Freezing Point | NA |
| pH | NA |
| Water Solubility | Partially soluble |
| Specific Gravity (Water =1) | NA |
| Water Reactivity | NA |

| | |
|-------------------|---------|
| Volatility | NA |
| Odor | No odor |

SECTION 10: STABILITY AND REACTIVITY

| | |
|---------------------------------|---|
| Stability | Stable under labeled storage conditions. |
| Incompatible Temperature | NA |
| Incompatible Materials | Oxidizing agents, bases. |
| Hazardous Polymerization | No |
| Hazardous Decomposition | When heated to decomposition the material emits very toxic fumes of HCl and NO _x |

SECTION 11: TOXICOLOGICAL INFORMATION

| | |
|-------------------------------|-----------------|
| Oral Rat: | LD50: 160 mg/kg |
| Oral Mouse | LD50: 227 mg/kg |
| Suspected Cancer Agent | No |

SECTION 12: ECOLOGICAL INFORMATION

| | |
|-----------------------------------|----|
| Environmental Stability | NA |
| Ecotoxicity | NA |
| Products of Biodegradation | NA |
| Special Remarks | NA |

SECTION 13: WASTE DISPOSAL

Dispose of material according to local, state, federal and environmental disposal regulations or company operating procedures.

SECTION 14: TRANSPORTATION INFORMATION

| | |
|---------------------------|---------------|
| DOT classification | Not hazardous |
| Identification | NA |

| | |
|------------------------------|----|
| DOT Label(s) Required | NA |
|------------------------------|----|

SECTION 15: REGULATORY INFORMATION

| | |
|---------------------------------------|----|
| US SARA Reporting Requirements | NA |
|---------------------------------------|----|

| | |
|--------------------------------------|----|
| Federal and State Regulations | NA |
|--------------------------------------|----|

| | |
|-----------------------------------|--|
| U.S. TSCA Inventory Status | Benzphetamine Hydrochloride is a “drug” as defined by the Federal Food, Drug, and Cosmetic Act and is therefore not a chemical substance under TSCA. |
|-----------------------------------|--|

SECTION 16: OTHER INFORMATION

DEFINITIONS OF ABBREVIATIONS USED:

| | |
|--------------|---|
| ACGIH | American Conference of Governmental Industry Hygienists |
|--------------|---|

| | |
|------------|---------------------------|
| CAS | Chemical Abstract Service |
|------------|---------------------------|

| | |
|-------------|---|
| IARC | International Agency for Research on Cancer |
|-------------|---|

| | |
|-------------|---|
| IDLH | Immediately Dangerous to Life or Health Level |
|-------------|---|

| | |
|------------------------|-----------------------------|
| LC₅₀ | Medial Lethal Concentration |
|------------------------|-----------------------------|

| | |
|------------------------|--------------------|
| LD₅₀ | Medial Lethal Dose |
|------------------------|--------------------|

| | |
|-------------|---------------------------------------|
| MSHA | Mine Safety and Health Administration |
|-------------|---------------------------------------|

| | |
|-----------|---------------|
| NA | Not Available |
|-----------|---------------|

| | |
|-----------|---------|
| ND | No Data |
|-----------|---------|

| | |
|-----------|-----------------|
| NE | Not Established |
|-----------|-----------------|

| | |
|--------------|---|
| NIOSH | National Institute for Occupational Safety and Health |
|--------------|---|

| | |
|------------|-----------------------------|
| NTP | National Toxicology Program |
|------------|-----------------------------|

| | |
|-------------|---|
| OSHA | Occupational Safety and Health Administration |
|-------------|---|

| | |
|------------|----------------------------|
| PEL | Permissible Exposure Limit |
|------------|----------------------------|

| | |
|-------------|--|
| SARA | Superfund Amendments and Reauthorization Act |
|-------------|--|

| | |
|-------------|---------------------------|
| STEL | Short Term Exposure Limit |
|-------------|---------------------------|

| | |
|------------|-----------------------|
| TLV | Threshold Limit Value |
|------------|-----------------------|

| | |
|------------|-----------------------|
| TWA | Time Weighted Average |
|------------|-----------------------|

SECTION 17: DISCLAIMER

The information contained in this Material Safety Data Sheet has been compiled from reliable sources and is believed to be correct as of the date issued. It is the responsibility of the user to determine the appropriateness and applicability to their situation. Paddock Laboratories, Inc. disclaims any expressed or implied warranty as to the accuracy of the above information and shall not be held liable for any direct, incidental, or consequential damages from use or reliance on the above information.